Aftab Dana, Chief Scientific Officer and EVP of Discovery & Translational Research, has exclusively traded shares of Exelixis (EXEL) over the past two years, with a clear pattern of disposition. Dana has executed no open-market purchases in the period reviewed, while generating $12.3 million in total sales across 24 transactions. The activity includes both discretionary sales (coded "S") and automatic dispositions (coded "F"), with the largest single sale occurring on February 24, 2026, when Dana sold $2.13 million worth of shares. Recent transactions show an acceleration in selling, with four sales in February 2026 alone totaling $5.4 million—including a $2.13 million sale on February 24 and a $1.32 million sale on February 19.
The transactions reveal a consistent reliance on automatic dispositions, particularly through "F"-coded transactions tied to tax obligations or prearranged trading plans. For example, on February 15, 2026, Dana disposed of $558,662 and $1.16 million worth of shares in separate filings. Prior to the 2026 sales, Dana had executed a $2.06 million discretionary sale on November 11, 2025, followed by multiple smaller dispositions throughout 2024 and 2025. The absence of any buy transactions suggests Dana has been systematically reducing exposure to EXEL, though the sales may be part of long-term portfolio management rather than a directional view on the stock.
AI-assisted summary